# Editorial: Dyslipidemia, prevention in the era of personalized medicine?

**Authors:** Amani Kallel, Maciej Banach

PMC · DOI: 10.3389/fmed.2025.1756918 · Frontiers in Medicine · 2026-02-11

## Full-text entities

- **Genes:** PCSK9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 255738] {aka FH3, FHCL3, HCHOLA3, LDLCQ1, NARC-1, NARC1}, APOB (apolipoprotein B) [NCBI Gene 338] {aka FCHL2, FLDB, LDLCQ4, apoB-100, apoB-48}
- **Diseases:** metabolic diseases (MESH:D008659), obesity (MESH:D009765), diabetes (MESH:D003920), carnitine deficiency (MESH:C536778), chronic kidney disease (MESH:D051436), metabolic syndrome (MESH:D024821), MASLD (MESH:D008107), coronary heart disease (MESH:D003327), Dyslipidemia (MESH:D050171), triglyceride abnormalities (MESH:C566030), type 2 diabetes (MESH:D003924), cholesterol abnormalities (MESH:C535937), CVD (MESH:D002318), atherosclerotic cardiovascular disease (MESH:D050197), hypertension (MESH:D006973)
- **Chemicals:** alcohol (MESH:D000438), lipid (MESH:D008055), bempedoic acid (MESH:C581236), L-carnitine (MESH:D002331)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12932138/full.md

---
Source: https://tomesphere.com/paper/PMC12932138